Background: Increasing evidence suggests that neuroglia, neuroimmune, and neuroinflammatory processes are involved in the development of nerve injury-induced pain and depression. Interferon regulatory factor 8 (IRF8), a crucial factor for microglial activation, is essential for the development of neuropathic pain. The brain-derived neurotrophic factor (BDNF) and inflammatory mediators (IL-1β, IL-6, and TNF-α) in the hippocampus contribute to the pathophysiology of neuropathic pain-depression comorbidity. Our previous study found that depressive-like behaviors induced by spared nerve injury (SNI) could be improved by applying pulsed radiofrequency (PRF) to the dorsal root ganglion (DRG) (PRF-DRG). However, the anti-depressive mechanisms of PRF-DRG therapy remain largely unknown. Methods: All rats (except for those in the sham group) were subjected to SNI. The nuclease-free water group and the IRF8 siRNA group were intrathecally injected with nuclease-free water and IRF8 siRNA on days 5 and 6 after SNI, respectively. PRF therapy on the L5 DRG was performed in the PRF group on day 7 after SNI, whereas no PRF current was delivered in the Sham-PRF group. The 50% paw withdrawal threshold, forced swimming test, and sucrose preference test were performed. The expression levels of spinal IRF8 and hippocampal BDNF were tested by molecular biochemistry, while IL-1β, IL-6, and TNF-α were tested by ELISA.Results: The depressive-like behaviors induced by SNI were remarkably developed in rats, which was indicated by a significant reduction in the sucrose preference rate and prolonged immobility time on day 42 after SNI. Mechanical allodynia and depression-like behaviors of rats with SNI were remarkably improved after PRF-DRG or intrathecal IRF8 siRNA. Spinal IRF8 overexpression, hippocampal BDNF downregulation, and increased hippocampal IL-1β and TNF-α levels were reversed by PRF-DRG, similar to the intrathecal injection of IRF8 siRNA. Conclusions: PRF-DRG therapy could regulate neuroimmune and neuroinflammatory responses to improve pain-induced depressive-like behaviors. The beneficial effect was correlated with the upregulation of BDNF and inhibition of IL-1β and TNF-α in the hippocampus via spinal IRF8 inactivation.